Case: Moderate-looking MR in advanced HFrEF — why context matters
A 72-year-old with HFrEF, dyspnea, and functional MR with EROA 0.24 cm². The MR does not meet ACC/AHA severe quantitative criteria — but it carries clinical importance in this ventricular context. What does that mean for management?
Clinical scenario
72-year-old man, HFrEF with LVEF 28%, progressive dyspnea on exertion, two HF admissions in the past year. TTE: ventricular functional MR, qualitative moderate, EROA 0.24 cm², regurgitant volume 34 mL/beat, regurgitant fraction 32%, LVEF 28%, LV markedly dilated (LVEDD 72 mm), PASP 58 mmHg. Current medications: carvedilol 6.25 mg twice daily, lisinopril 5 mg daily, furosemide 40 mg daily. No SGLT2 inhibitor, ARNI, or MRA documented.
What does 'moderate-looking MR' mean in this patient, and what should happen next?
Interpreting the MR grade
By ACC/AHA VHD 2020 quantitative criteria, the provided data do not meet the severe secondary MR range. EROA 0.24 cm² is below the severe threshold of ≥ 0.40 cm², and regurgitant volume 34 mL/beat is below ≥ 60 mL/beat. The qualitative grade is moderate. A tool output of 'severe secondary MR' from these inputs alone would be inaccurate.
However, this MR is not dismissible. EROA 0.24 cm² lies in a range that has been associated with worse outcomes in secondary MR populations — not because the severe threshold has been crossed, but because in a markedly dilated LV with LVEF 28%, even moderate MR may add clinically meaningful volume load. This MR, in a ventricle with already elevated filling pressures, may worsen pulmonary congestion and contribute to symptoms and HF trajectory.
EROA 0.24 cm² is not severe — but it is not dismissible
This patient should not be labeled as having guideline-severe secondary MR. But the MR should not be ignored. This is the type of finding this tool classifies as 'clinically important secondary MR in context.' The correct next step is not to rush to valve intervention — it is to optimize HF therapy and reassess after treatment.
Why GDMT comes first
This patient is not on optimized GDMT. The beta-blocker dose is low, the ACE inhibitor dose is low, and no SGLT2 inhibitor, ARNI, or MRA is documented. Diuretic therapy is present but does not substitute for disease-modifying HF therapy. In HFrEF, ACEi/ARB/ARNI, beta-blocker, MRA, and SGLT2 inhibitor therapy should be optimized to the maximum tolerated regimen. Reverse remodeling may reduce LV size, filling pressure, and the geometric basis for secondary MR.
Reassess symptoms, LVEF, LV size, PASP, and MR severity after approximately 3–6 months of optimized therapy when clinically feasible. If confirmed severe secondary MR persists despite maximally tolerated GDMT and the patient remains symptomatic, then TEER evaluation becomes appropriate — provided COAPT-like clinical and anatomic criteria are met.
Perioperative implication
If this patient presents for elective noncardiac surgery, the dominant concern is not the label 'moderate MR' alone. The larger problem is poorly optimized, high-risk HFrEF with LVEF 28%, PASP 58 mmHg, progressive symptoms, and recent HF admissions. PASP 58 mmHg suggests pulmonary hypertension and is an important perioperative risk marker. For elective surgery, HF optimization and reassessment should be prioritized when feasible. If surgery is urgent or time-sensitive, the perioperative plan should include invasive arterial pressure monitoring, vasoactive/inotrope planning, careful fluid strategy, and postoperative critical care planning.
What is the next step for this patient?
- 1.Optimize GDMT — consider ARNI transition, uptitrate beta-blocker as tolerated, add SGLT2 inhibitor and MRA, and reassess MR in 3–6 months✓ Recommended
Correct. This patient is on suboptimal HFrEF therapy. GDMT may improve LV remodeling and reduce MR. Medical optimization is first-line.
- 2.Refer for TEER because EROA is above 0.20 cm²⚠ Not recommended
Not appropriate. EROA 0.24 cm² may be clinically important in context, but it does not meet ACC/AHA severe secondary MR criteria. GDMT is also not optimized. TEER should be considered only when symptomatic confirmed severe secondary MR persists despite optimized therapy and COAPT-like criteria are met.
- 3.Refer for cardiac surgery consultation for annuloplasty⚠ Not recommended
Not appropriate at this stage. Surgical mitral intervention for secondary MR is generally reserved for specific contexts, such as when another cardiac surgery such as CABG is being performed. GDMT optimization should come first.
Teaching points
- EROA 0.24 cm² is below the ACC/AHA severe secondary MR quantitative range — 'clinically important in context' is not the same as guideline-severe.
- In a markedly dilated LV with LVEF 28%, moderate MR may still carry prognostic and clinical importance.
- GDMT optimization is first-line — MR may improve in some patients after reverse remodeling.
- TEER evaluation is premature before GDMT is optimized and severe MR is confirmed.
- COAPT-like intervention evaluation applies to patients with persistent symptomatic severe secondary MR despite maximally tolerated GDMT.
- For perioperative physicians, HF stability, LVEF, PASP, RV function, and recent HF admissions matter more than MR grade alone.
Apply this in practice
Use the Secondary MR Severity Tool to evaluate severity, then proceed to the Intervention Navigator after GDMT is optimized.
Secondary MR Severity Tool